1 Shuji A. Role of angiotensin II and endogenous vasodilators in the control of glomerular hemodynamics[J]. Clin Exp Nephrol, 2003;7:172-8
2 William FK, Kiyoshi K, Paulette AL, Shahnaz S, Thomas PS, Kenneth KW, et al.Treatment of type 2 diabetic patients with kidney disease with AT1-receptor antagonists:lessons from recent trials[J]. Clin Exp Nephrol, 2002;6:175-81
3 Satoru M, Tsutomu H, Taro S, Kenta O, Reiko I, Mitsuru A. Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure[J]. Hypertens Res, 2003; 26:453-8
4 Yasuhiko I, Matsuhiko H, Tetsuya K, Tatsuo S, Yasuhiko T, Kenichi Y, et al.Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the japanese losartan therapy intended for global renal protection in hypertensive patients (jlight) study[J]. Clin Exp Nephrol, 2003; 7:221-30
5 Yasuaki D, Masuo O, Masaya S, Hiroyuki T, Koichi S, Ryuzo U.Candesartan reduces oxidative stress and inflammation in patients with essential hypertension[J]. Hypertens Res, 2003; 26:691-7
6 Lajemi M, Labat C, Gautier S, Lacolley P, Safar M, Asmar R, et al.Angiotensin II type 1 receptor-153 A G and 1166 A C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects[J]. J Hypertens, 2001; 9:407-13
7 Anan F, Takahashi N, Ooie T, Hara M, Yoshimatsu H, Saikawa T.Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance[J]. Metabolism, 2004;53:777-81
8 Yoshida O, Hirayama H, Nanasato M, Watanabe T, Murohara T.The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation:a prospective randomized study under intravascular ultrasound guidance[J]. Am Heart J, 2005; 149:2
9 Roberto F, Amedeo M, Annalisa Z, GianluigiM, Carlo P, Luigi P, et al.Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension[J]. Eur J Clin Pharmacol, 2004; 59:863-8
10 Nagisa YA, Shintani SN.The angiotensin II receptor antagonistcandesartan cilexetil (TCV-116) ameliorates retinal disorders in rats[J]. Diabetologia, 2001; 44:883-8
11 Caiying G, Haisong J, Debbie L, HamidM, Mingda SMR. A novel vascular smooth muscle chymase is upregulated in hypertensive rats[J]. J Clin Invest, 2001;107: 703-15
12 Doggrell SA, Wanstall JC.Vascular chymase: pathophysiological role and therapeutic potential of inhibition[J]. Cardiovasc Res, 2004; 61:653-62
13 Mizuo M, Shinji T.Local angiotensin II-generating system in vascular tissues: the roles of chymase[J]. Hypertens Res, 2001; 24:189-93
14 Shiota N, Okunishi H, Takai S, Mikoshiba I, Sakonjo H, Shibata N, et al.Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery[J]. Circulation, 1999;99: 1084-90
15 Nishimoto M, Takai S, Kim S, Jin D, Yuda A, SakaguchiM, et al.Singigicance of chymase dependent angiotensin II -forming pathway in vascular proliferation[J]. J Hypertens, 2000; 18:S90
16 Li P, Chen PM, Wang SW, Chen LY.Time-dependent expression of chymase and angiotensin converting enzyme in the hamster heart under pressure overload[J]. Hypertens Res, 2002; 25:757-62
17 Hirobumi T, Koichi H, Hiroto M, Eiji K, Masanori H, Ken O, et al.Differential regulation of elevated renal angiotensin II in chronic renal ischemia[J]. Hypertension, 2002;40: 34
18 Morikawa T, Imanishi M, Suzuki H, Okada N, Okumura M, Konishi Y, et al.Mast cell chymase in the ischemic kidney of severe unilateral renovascular hypertension[J]. Am J Kidney Dis, 2005; 45:45-50
19 Huang XR, Chen WY, Truong LD.Chymase is up-regulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease[J]. J Am Soc Nephrol, 2003;14:1738-47
20 McPherson EA, Luo Z, Brown RA, LeBard LS, Corless CC, Speth RC, et al.Chymase-like angiotensin II-generating activity in end-stage human autosomal dominant polycystic kidney disease[J]. J Am Soc Nephrol, 2004; 15:493-500
21 Huang LL, Daniel JS, Kirsten S, Mary D, Rodger S, Indra S, et al.Novel peptide inhibitors of angiotensin-converting enzyme 2[J]. J Biol Chem, 2003;278: 15532-40
22 Lely AT, Hamming I, van Goor H, Navis GJ.Renal ACE2 expression in human kidney disease[J]. J Pathol, 2004; 204:587-93
23 Burrell LM, Johnston CI, Tikellis C, Cooper ME.ACE2, a new regulator of the renin-angiotensin system[J]. Trends Endocrinol Metab, 2004;15:166-9
24 Kuhn JH, Li W, Choe H, Farzan M.Angiotensin-converting enzyme 2:a functional receptor for SARS coronavirus[J]. Cell Mol Life Sci, 2004;61: 2738-43 |
